AFC
TEVA icon

Ares Financial Consulting’s Teva Pharmaceuticals TEVA Stock Holding History

Ares Financial Consulting’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.18K Sell
153
-60
-28% -$2K ﹤0.01% 702
2026
Q1 		$6.44K Buy
+213
New +$6.85K 0.01% 638

Other funds holding TEVA

HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.63B AUM 45.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return
YDMI
Y.D. More Investments Ramat Gan, Israel $3.21B AUM 117.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Ares Financial Consulting's TEVA Position: Q2 2026 in Review

Ares Financial Consulting reduced its Teva Pharmaceuticals (TEVA) stake by 28% in Q2 2026, selling an estimated $2K and leaving 153 shares worth $5.18K. The position accounts for ﹤0.01% of the portfolio, ranked #702.

Ares Financial Consulting first reported a position in TEVA in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.44K in Q1 2026. 307 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Ares Financial Consulting held 153 shares of Teva Pharmaceuticals worth $5.18K as of Q2 2026.
  • Ares Financial Consulting sold 60 Teva Pharmaceuticals shares in Q2 2026, an estimated $2K.
  • Teva Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #702 holding.
  • Ares Financial Consulting first reported a position in Teva Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Ares Financial Consulting's Teva Pharmaceuticals position peaked at $6.44K in Q1 2026.
  • 307 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.